Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children
An Open-label Study of Liquid and Sprinkled Formulations of Efavirenz Administered in Combination With Didanosine and Emtricitabine in HIV-infected Infants and Children 3 Months to 6 Years of Age.
Sponsor: Bristol-Myers Squibb
Listed as NCT00364793, this PHASE1/PHASE2 trial focuses on HIV Infections and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 8 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bangkok, Thailand , Bloemfontein, South Africa , Buenos Aires, Argentina , Cali, Colombia , Cape Town, South Africa , Capital Federal, Argentina , Colima, Mexico , Df, Mexico , Guadalajara, Mexico , Monterrey, Mexico and 5 more locations